At Personalis, we’re driven by the powerful idea that every instance of cancer is personal – and that the active management of cancer, from detecting recurrence at the earliest possible timepoint to tracking individual response to treatment, should be personal, too.
Ultimately, we aim to help transform the next standard of care in partnership with leaders in oncology. There have been many milestones along the way, and today, we are thrilled to share a pivotal one.
We recently announced a new agreement to continue our work with Moderna, a biotechnology company pioneering mRNA therapeutics and vaccines, to support Moderna’s development of personalized cancer vaccines (PCVs). For years, Personalis has been at the forefront of working with pharmaceutical partners, including Moderna, to realize the promise of PCVs – which have the potential to improve outcomes for thousands of cancer patients each year. This partnership is part of a broader strategy for our proprietary technology to become embedded in the manufacturing process for companies developing PCVs.
Personalis is strategically suited on two fronts to partner with companies developing PCVs: First, as an engine for powering personalized vaccine design, and second, for enabling patient-specific monitoring of therapy response. Our technology is differentiated by our proprietary ACE® process, which ensures uniform sequencing across the entire exome, as well as the ability to determine neoantigens that can be targeted by the vaccines. And, our NeXT Personal® MRD platform enables detection of potential recurrence and response to therapy up to many months earlier than other technologies.
Our partnership with Moderna represents a nexus point where multiple technological and scientific advancements meet. For more details about today’s announcement, see our press release.
